Geneva Partners’s Curis CRIS Stock Holding History

Geneva Partners’s Portfolio CRIS Stock Details CRIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10	Closed	-$13K	–	87
2018 Q1	$13K	Hold	10	–	–	0.01%	76
2017 Q4	$14K	Hold	10	–	–	0.01%	84
2017 Q3	$29K	Buy	+10	New	+$37K	0.02%	88

Other funds holding CRIS

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arnhold LLC New York $1.36B AUM 53.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geneva Partners's CRIS Position: Q2 2018 in Review

Geneva Partners sold out of Curis (CRIS) in Q2 2018, closing a stake of 10 shares — an estimated $13K sold.

Geneva Partners first reported a position in CRIS in Q3 2017 and held it in 3 quarters. The position peaked at $29K in Q3 2017. 57 funds tracked by Wall St. Rank hold CRIS as of Q2 2018.

Geneva Partners reported no remaining Curis position as of Q2 2018 after selling out during the quarter.
Geneva Partners sold 10 Curis shares in Q2 2018, an estimated $13K.
Geneva Partners first reported a position in Curis in Q3 2017 and held it in 3 quarters.
Geneva Partners's Curis position peaked at $29K in Q3 2017.
57 funds tracked by Wall St. Rank held Curis as of Q2 2018.

Based on Geneva Partners's 13F filing for Q2 2018, filed 9 Aug 2018.